arrow_back Back to App

Faster Generic Drug Access: Protecting Competition and Lowering Prescription Costs.

This law aims to reduce prescription drug costs by accelerating the market entry of cheaper generic and biosimilar alternatives. It creates a legal 'safe harbor,' protecting generic manufacturers from patent infringement lawsuits if they market their drugs only for uses that are not patented, using restricted 'skinny labels.' This change is expected to increase competition and lower prices for consumers, leading to personal savings.
Key points
Generic drug makers can launch products by excluding patented uses from their labeling, without being sued for infringing the patent on that specific method of use.
The goal is to boost market competition, leading directly to lower prices for many prescription medications for patients.
The protection applies only if the generic company does not promote the drug for the specific patented condition or use.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_6485
Sponsor: Rep. Cline, Ben [R-VA-6]
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Skinny Labels, Big Savings Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_6485.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What are the main provisions?

Key points include:

  • Generic drug makers can launch products by excluding patented uses from their labeling, without being sued for infringing the patent on that specific method of use.
  • The goal is to boost market competition, leading directly to lower prices for many prescription medications for patients.
  • The protection applies only if the generic company does not promote the drug for the specific patented condition or use.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Cline, Ben [R-VA-6].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on the Judiciary.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-31.

CATEGORIES

Health Courts and Law